Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24064911 | 0.81 | ALOX15 (0.65) | ALDH1A1KMT2AKDM4EHSD17B10TSHR | |
| SCHEMBL3085221 | 0.80 | ALDH1A1 (0.52) | HIF1AALDH1A1GAAPOLBKMT2A | |
| SCHEMBL2443510 | 0.78 | ALDH1A1 (0.48) | HIF1AALDH1A1GAAPOLBKMT2A | |
| SCHEMBL17525717 | 0.78 | ALDH1A1 (0.48) | HIF1AALDH1A1GAAPOLBKMT2A | |
| SCHEMBL9615855 | 0.77 | BCL2 (0.46) | ALDH1A1GAAPOLBPKM | |
| SCHEMBL14843790 | 0.76 | HSD17B10 (0.51) | ALDH1A1GAAKMT2ATP53HPGD | |
| SCHEMBL31690313 | 0.76 | HSD17B10 (0.51) | ALDH1A1GAAKMT2ATP53HPGD | |
| SCHEMBL24064898 | 0.76 | MAPT (0.49) | ALDH1A1KDM4EHSD17B10TSHRL3MBTL1 | |
| SCHEMBL392680 | 0.75 | ALDH1A1 (1.00) | HIF1AALDH1A1GAAPOLBKMT2A | |
| SCHEMBL4861809 | 0.75 | ALDH1A1 (1.00) | HIF1AALDH1A1GAAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003187-B | Polyfluoroalkyl substituted benzofuran compound and preparation method thereof | 南京工业大学 | 2021-11-05 | — | — | CN | claimed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| CN-110003187-B | Polyfluoroalkyl substituted benzofuran compound and preparation method thereof | 南京工业大学 | 2021-11-05 | — | — | CN | disclosed |
| US-20070196395-A1 | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain | UNIVERSITY OF MARYLAND, BALTIMORE | 2007-08-23 | — | — | US | disclosed |
| US-20070196395-A1 | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain | UNIVERSITY OF MARYLAND, BALTIMORE | 2007-08-23 | — | — | US | disclosed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-0706521-B1 | IMIDES AS TNF ALPHA INHIBITORS | CELGENE CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1004572-A2 | Amines as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004580-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5463063-A | Preparation of thalidomide; inhibitor of tumor necrosis factor | CELGENE CORPORATION (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196395-A1 | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain | LCK, PTPN6, PTPN22 | HIF1A 4552/4885ALDH1A1 4878/4885GAA 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.